Autolus Therapeutics (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
$1.33
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.33
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.11 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.53M
Market Cap
$353.97M
Enterprise Value$323.04M
Total Cash (Recent Filing)$367.41M
Total Debt (Recent Filing)$65.83M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 27, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding266,143,280
10 Day Avg. Volume1,341,335
30 Day Avg. Volume1,527,644
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.32
Enterprise Value/Gross Profit-2.04
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$8.00Price Target Upside501.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$135.66M
Bulls Say, Bears Say
Bulls Say
Clinical Expansion PotentialAnalyst highlights that the commercially approved autologous CAR-T therapy and upcoming pivotal data readouts could enable label expansion into autoimmune and pediatric oncology indications, materially expanding the addressable market.
Commercial Execution And Unit EconomicsAnalyst cites an established commercial footprint, a strong initial product launch, and ongoing manufacturing optimization that are expected to improve gross margins and unit economics as more treatment centers onboard.
Proprietary Technology And SafetyAnalyst emphasizes the proprietary CAT19 binder's fast off-rate kinetics enable targeted B cell depletion with reconstitution of healthy naive B cells, supporting a differentiated safety and durability profile attractive for chronic autoimmune use.
Bears Say
Guidance ShortfallAnalyst reports company guidance came in meaningfully below estimates and consensus, prompting downward revisions to sales forecasts and analyst price targets.
Reimbursement And Patient Starts DisruptionAnalyst notes a reimbursement coding change that slowed patient starts and contributed to flat revenue growth, creating uncertainty around commercial momentum.
Valuation Pressure From Share DeclineAnalyst notes shares have declined to trade near cash value, reflecting investor concern and limiting upside until revenue growth and guidance visibility improve.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.10 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $353.97M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Mar 27, 2026 which is today.
How were Autolus Therapeutics’s earnings last quarter?
Currently, no data Available
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,143,280 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (501.50% Upside)
$8.00 (501.50% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 147.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.90%
12-Months-Change
Fundamentals
Return on Equity
-63.76%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.00
▲(501.50% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.48% Mutual Funds
40.17% Other Institutional Investors
58.68% Public Companies and Individual Investors